MA34469B1 - Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci - Google Patents

Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci

Info

Publication number
MA34469B1
MA34469B1 MA35664A MA35664A MA34469B1 MA 34469 B1 MA34469 B1 MA 34469B1 MA 35664 A MA35664 A MA 35664A MA 35664 A MA35664 A MA 35664A MA 34469 B1 MA34469 B1 MA 34469B1
Authority
MA
Morocco
Prior art keywords
preparation
therapeutic use
anticancer
anticancer derivatives
derivatives
Prior art date
Application number
MA35664A
Other languages
English (en)
Inventor
Alain Commercon
Laurence Gauzy-Lazo
Philippe Hubert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43027561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34469(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34469B1 publication Critical patent/MA34469B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des conjugués de dimère de pyrrolo[1,4]benzodiazépine (PBD), des compositions les incluant et leurs applications thérapeutiques, spécialement en tant qu'agents anticancéreux. La présente invention concerne également le procédé de synthèse des conjugués et leur utilisation en tant qu'agents anticancéreux, ainsi que les dimères eux-mêmes. Formule (I) où : représente une liaison simple ou une liaison double.
MA35664A 2010-07-26 2011-07-25 Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci MA34469B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1056103A FR2963007B1 (fr) 2010-07-26 2010-07-26 Derives anticancereux, leur preparation et leur application therapeutique
PCT/IB2011/053310 WO2012014147A1 (fr) 2010-07-26 2011-07-25 Dérivés anticancéreux, leur synthèse et leurs applications thérapeutiques

Publications (1)

Publication Number Publication Date
MA34469B1 true MA34469B1 (fr) 2013-08-01

Family

ID=43027561

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35664A MA34469B1 (fr) 2010-07-26 2011-07-25 Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci

Country Status (31)

Country Link
US (1) US9056914B2 (fr)
EP (1) EP2598507B1 (fr)
JP (1) JP5814366B2 (fr)
KR (1) KR20130094806A (fr)
CN (1) CN103140491B (fr)
AR (1) AR082341A1 (fr)
AU (1) AU2011284339B2 (fr)
BR (1) BR112013001978B1 (fr)
CA (1) CA2806665A1 (fr)
CL (1) CL2013000250A1 (fr)
CO (1) CO6650375A2 (fr)
CR (1) CR20130035A (fr)
DO (1) DOP2013000021A (fr)
EA (1) EA201390162A1 (fr)
EC (1) ECSP13012404A (fr)
ES (1) ES2638520T3 (fr)
FR (1) FR2963007B1 (fr)
GT (1) GT201300025A (fr)
MA (1) MA34469B1 (fr)
MX (1) MX2013001069A (fr)
MY (1) MY159197A (fr)
NI (1) NI201300010A (fr)
NZ (1) NZ606246A (fr)
PE (1) PE20130489A1 (fr)
PH (1) PH12013500154A1 (fr)
SG (1) SG187191A1 (fr)
TW (1) TW201208689A (fr)
UA (1) UA111164C2 (fr)
UY (1) UY33531A (fr)
WO (1) WO2012014147A1 (fr)
ZA (1) ZA201300685B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016044396A1 (fr) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugués comprenant des anticorps anti-her2 et des pyrrolobenzodiazépines
WO2016115191A1 (fr) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Dimères de benzodiazépine, conjugués de ceux-ci, et procédés de fabrication et d'utilisation
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
EA201792516A1 (ru) 2015-06-23 2018-05-31 Бристол-Маерс Сквибб Компани Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение
NZ741261A (en) 2015-10-02 2019-11-29 Genentech Inc Pyrrolobenzodiazepine antibody drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
CN115466231B (zh) * 2022-10-23 2024-03-08 浙江大学 管道化制备3-[2-(4-吗啉基)乙氧基]丙腈的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5093475A (en) 1988-12-22 1992-03-03 Xoma Corporation Hindered linking agents derived from 2-iminothiolanes and methods
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2341471C (fr) 1998-08-27 2009-04-07 Spirogen Limited Composes
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
CR20170291A (es) 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
MXPA06000830A (es) 2003-07-21 2006-04-18 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
WO2005040170A2 (fr) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
EP1669358A1 (fr) 2004-12-07 2006-06-14 Aventis Pharma S.A. Agents cytotoxiques comprenant des nouveau taxanes
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
JP2009526778A (ja) * 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
EP1832577A1 (fr) 2006-03-07 2007-09-12 Sanofi-Aventis Promédicament amélioré d'analogues de CC-1065
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
SI2019104T1 (sl) * 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2185188B1 (fr) 2007-08-22 2014-08-06 Medarex, L.L.C. Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
FR2939795B1 (fr) 2008-12-17 2010-12-17 Sanofi Aventis Procede de preparation d'esters actives
SG173152A1 (en) * 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody

Also Published As

Publication number Publication date
CL2013000250A1 (es) 2013-04-12
ES2638520T3 (es) 2017-10-23
GT201300025A (es) 2014-07-11
UY33531A (es) 2012-02-29
FR2963007A1 (fr) 2012-01-27
AU2011284339B2 (en) 2015-11-05
AU2011284339A1 (en) 2013-02-14
SG187191A1 (en) 2013-02-28
CA2806665A1 (fr) 2012-02-02
US20130137659A1 (en) 2013-05-30
TW201208689A (en) 2012-03-01
CR20130035A (es) 2013-03-04
US9056914B2 (en) 2015-06-16
BR112013001978B1 (pt) 2020-03-03
ZA201300685B (en) 2014-10-29
MX2013001069A (es) 2013-12-02
DOP2013000021A (es) 2013-04-15
JP2013532680A (ja) 2013-08-19
WO2012014147A1 (fr) 2012-02-02
CN103140491A (zh) 2013-06-05
MY159197A (en) 2016-12-30
ECSP13012404A (es) 2013-03-28
UA111164C2 (uk) 2016-04-11
PH12013500154A1 (en) 2013-02-18
CN103140491B (zh) 2016-08-10
NI201300010A (es) 2013-05-13
FR2963007B1 (fr) 2013-04-05
EP2598507B1 (fr) 2017-05-31
EA201390162A1 (ru) 2013-11-29
KR20130094806A (ko) 2013-08-26
CO6650375A2 (es) 2013-04-15
EP2598507A1 (fr) 2013-06-05
AR082341A1 (es) 2012-11-28
NZ606246A (en) 2015-04-24
BR112013001978A2 (pt) 2016-05-24
JP5814366B2 (ja) 2015-11-17
PE20130489A1 (es) 2013-05-08

Similar Documents

Publication Publication Date Title
MA34469B1 (fr) Dérivés anticancéreux, préparation de ceux-ci et utilisation thérapeutique de ceux-ci
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
MY157469A (en) Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MX2010009646A (es) Agentes terapeuticos antivirales.
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MX2007001059A (es) Conjugados de fosfonato de nucleosido como agentes contra vih.
EP2289891A3 (fr) Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique.
MX368966B (es) Conjugados de proteina-polimero-farmaco.
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MA43160B1 (fr) Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique
UA107455C2 (uk) Похідні індолу як протиракові агенти
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
EA200501870A1 (ru) Новые производные имидазолов, способ их получения и их применение в качестве лекарственного средства
AR114134A2 (es) Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
MA42988B1 (fr) Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA34910B1 (fr) Dérivés de 2-methoxy-pyridin-4-yl
MA33916B1 (fr) Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
MA30496B1 (fr) Derives de 2-alcoxy -3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation